Chart - you can draw at the chart
Starting Amount
$
After
years
Dividend yield
%
Dividends reinvested
$
Accelrys Inc.
Type
Public
Traded as NASDAQ: ACCL no longer traded after acquisition by Dassault Systèmes
Industry Life sciences, Materials science, CPG, Automotive, Aerospace, Energy, Academic, Manufacturing, Technology
Founded 2001
Headquarters San Diego, California, United States
Cambridge, United Kingdom
Tokyo, Japan
Key people
Max Carnecchia (CEO)
Jason Gray, General Counsel
Matt Hahn, Senior Vice President and Chief Technology Officer
Leif Pedersen, Senior Vice President of Marketing, Product Management and Corporate Development
Revenue US$155 million
Number of employees
700+
Website www.accelrys.com

Accelrys is a software company headquartered in the United States, with representation in Europe and Asia. It provides software for chemical, materials and bioscience research for the pharmaceutical, biotechnology, consumer packaged goods, aerospace, energy and chemical industries.

It is a wholly owned subsidiary of Dassault Systèmes after an April 2014 acquisition and has been renamed BIOVIA.

Accelrys was formed in 2001 as a wholly owned subsidiary of Pharmacopeia, Inc. from the fusion of five companies: Molecular Simulations Inc. (MSI, itself a result of the combination of Biodesign, Cambridge Molecular Design, Polygen and, later, Biocad and Biosym Technologies), Synopsys Scientific Systems, Oxford Molecular, the Genetics Computer Group (GCG), and Synomics Ltd.

In late 2003, Pharmacopeia, Inc. separated its drug discovery and software development businesses. The drug discovery company retained the name Pharmacopeia and remained in Princeton, New Jersey, with ~170 employees. The software company, with ~530 employees and 2002 revenue of $95.1 million would move to San Diego, California.

In 2004, Accelrys acquired SciTegic, producer of the Pipeline pilot software.

On Dec 22, 2005, Accelrys, Inc. announced to restate its historical financial statements, to reflect changes to the timing of revenue recognition on certain historical term-based contracts, substantially all of which were entered into prior to January 2004.

Accelrys managed a nanotechnology consortium producing software tools for rational nanodesign from 2004 to 2010.

In 2010, Symyx Technologies was merged with Accelrys.

In May 2011, the company acquired Contur Software AB, an electronic lab notebook software firm.

In January 2012, Accelrys acquired VelQuest, a maker of pharmaceutical and medical device-related software, for $35 million in cash.

In May 2012, Accelrys purchased Hit Explorer Operating System (HEOS) - a SaaS system that provides groups with project information in the cloud and access to biological assay results, analytics, chemical registration and pharmacokinetics data - from Scynexis.

In October 2012, Accelrys acquired Aegis Analytical Corp. for $30 million in cash, expanding Accelrys’ reach for customers in the move from the lab to the manufacturing floor. The company’s Discoverant software aggregates and analyzes manufacturing, quality and development data to allow manufacturers for quality by design.

In January 2013, Accelrys acquired Swiss biosciences systems integrator Vialis AG for $5 million in cash.

In September 2013, Accelrys acquired Environmental Health & Safety (EH&S) compliance provider ChemSW.

On January 30, 2014 Dassault Systèmes of France announced the acquisition of Accelrys in an all-cash tender offer for at $12.50 per share, representing a fully diluted equity value for Accelrys of approximately $750 million. After the acquisition Accelrys was renamed BIOVIA.

Commercial versions of otherwise academically licensed programs:

Investment goal date:
Dividends reinvested
Accelrys Inc. ACCL report
Period
Date
Adjusted Actuals EPS
GAAP EPS
There is presents forecasts or rating agencies and recommendation for investors about this ticker
Funds
Fund Name
Ticker shares
Major Shareholders
Name Relationship
Total Shares
Holding stocks
COLEMAN KENNETH L
0.0200% (9727)
ACCL / CYN / UNTD /
GOLDBY STEVEN D
0.0100% (6000)
ACCL / LNDC /
HERITAGE TREVOR
0.0300% (17000)
ACCL /
Steffen Christopher J
0.0200% (9000)
ACCL / GRA / PTP / VIAS /
RGM Capital, LLC
12.8400% (7144932)
ACCL / GUID / SPRT /
MERSTEN DAVID R
0.0400% (25000)
ACCL /
Pasternack Bruce A
0.0200% (9000)
ACCL / CDXS /
Brown Frank K
0.0100% (5087)
ACCL /
% ()